RCS - Ondine Biomedical - Canada's Largest Cardiac Centre Adopts Steriwave

Ondine BiomedicalAnnouncement

05/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE4998La&default-theme=true

RNS Number : 4998L  Ondine Biomedical Inc.  05 June 2025

5(th) June 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Canada's Largest Cardiac Centre Adopts Steriwave

Ottawa Heart Institute Adopts Ondine's Steriwave(®) Nasal Photodisinfection
as Standard of Care for Cardiac Surgeries

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that the University
of Ottawa Heart Institute ("OHI"), one of Canada's leading cardiac care
centres, has adopted Steriwave(®) nasal photodisinfection as a standard of
care for all cardiac surgeries. This decision reinforces OHI's commitment to
patient safety and innovation in infection prevention.

OHI is Canada's largest and foremost cardiovascular health centre, recognized
internationally for its world-class expertise in cardiac care, research, and
education. Serving as a major referral centre for Eastern Ontario, OHI
provides advanced cardiac surgery, interventional cardiology, and
comprehensive patient care to thousands of patients each year. The Institute
is renowned for its pioneering research, innovative clinical programs, and
commitment to patient safety and outcomes. OHI's multidisciplinary teams are
dedicated to advancing the prevention, diagnosis, and treatment of heart
disease, making OHI a leader in cardiovascular innovation both in Canada and
globally.

The Ottawa Heart Institute joins a growing number of leading hospitals,
including Vancouver General Hospital, The Ottawa Hospital, Mazankowski Alberta
Heart Institute, University of Alberta Hospital and other major Canadian and
UK institutions that have successfully implemented Steriwave nasal
decolonization in their pre-surgical protocols. Clinical deployments have
demonstrated significant reductions in SSI (surgical site infection) rates,
further validating Steriwave as an effective and innovative solution for
infection control.

Carolyn Cross, CEO of Ondine Biomedical:

"We are extremely pleased to be supporting the Ottawa Heart Institute's
efforts to address multidrug resistance and enhance their patient protection
protocols. By adopting Steriwave as standard of care, OHI is once again
demonstrating its leadership in clinical excellence and its commitment to
staying at the forefront of infection prevention. We are honoured to partner
with such a forward-thinking institution, and we look forward to supporting
OHI as they continue to set new benchmarks in patient protection and
antimicrobial stewardship."

Steriwave photodisinfection is a light-activated, non-antibiotic antimicrobial
therapy that rapidly eradicates all types of nasal pathogens associated with
surgical site infections without generating resistance or relying on patient
compliance. Unlike currently used antimicrobials, Steriwave provides
full-spectrum nasal decolonization in minutes, offering a powerful new tool in
the fight against healthcare-associated infections and antibiotic resistance.
Steriwave continues to gain recognition with a proven track record of
improving surgical outcomes and reducing healthcare costs.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZLFBEQLBBBE